Table 1 Acute and late side effects according to EORTC-RTOG grades and IPSS score.
Acute GU side effects | Acute GI side effects | Cumulative late GU side effects | Cumulative late GI side effects | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Whole cohort | Cyberknife treated group | p | Whole cohort | Cyberknife treated group | p | Whole cohort | Cyberknife treated group | p | Whole cohort | Cyberknife treated group | p | |
grade 0 | 16 (32.7%) | 5 (14.3%) | 0.1465 | 40 (81.6%) | 26 (74.3%) | 0.7209 | 24 (49.0%) | 16 (45.7%) | 0.9794 | 44 (89.8%) | 30 (85.7%) | 0.5690 |
grade 1 | 8 (16.3%) | 6 (17.1%) | 8 (16.3%) | 8 (22.9%) | 14 (28.6%) | 10 (28.6%) | 5 (10.2%) | 5 (14.3%) | ||||
grade 2 | 25 (51.0%) | 24 (68.6%) | 1 (2.0%) | 1 (2.9%) | 9 (18.4%) | 7 (20.0) | 0 | 0 | ||||
grade 3 | 0 | 0 | 0 | 0 | 2 (4.1%) | 2 (5.7%) | 0 | 0 | ||||
Acute IPSS score | Cumulative late IPSS score | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Whole cohort | Cyberknife treated group | p | Whole cohort | Cyberknife treated group | p | |||||||
mild (0–7) | 35 (71.4%) | 23 (65.7%) | 0.6744 | 14 (28.6%) | 7 (20.0%) | 0.8334 | ||||||
moderate (8–19) | 10 (20.4%) | 7 (20.0%) | 28 (57.1%) | 22 (62.9%) | ||||||||
severe (20–35) | 3 (6.1%) | 4 (11.4%) | 7 (14.3%) | 6 (17.1%) | ||||||||
